<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001519" GROUP_ID="MOVEMENT" ID="743800021014284605" MERGED_FROM="" MODIFIED="2015-12-16 10:56:48 +0000" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-12-16 10:56:48 +0000" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2015-12-16 10:56:48 +0000" MODIFIED_BY="Ema Roque">
<TITLE>Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease</TITLE>
<CONTACT>
<PERSON ID="14796" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Carl</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Clarke</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Clinical Neurology</POSITION>
<EMAIL_1>c.e.clarke@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>College of Medical and Dental Sciences</ORGANISATION>
<ADDRESS_1>University of Birmingham</ADDRESS_1>
<ADDRESS_2>Edgbaston</ADDRESS_2>
<CITY>Birmingham</CITY>
<ZIP>B18 7QH</ZIP>
<REGION>West Midlands</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 121 507 4073</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 121 507 5442</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-12-16 10:55:27 +0000" MODIFIED_BY="Ema Roque">
<PERSON ID="14796" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Carl</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Clarke</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Clinical Neurology</POSITION>
<EMAIL_1>c.e.clarke@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>College of Medical and Dental Sciences</ORGANISATION>
<ADDRESS_1>University of Birmingham</ADDRESS_1>
<ADDRESS_2>Edgbaston</ADDRESS_2>
<CITY>Birmingham</CITY>
<ZIP>B18 7QH</ZIP>
<REGION>West Midlands</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 121 507 4073</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 121 507 5442</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11150" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Katherine</FIRST_NAME>
<MIDDLE_INITIALS>HO</MIDDLE_INITIALS>
<LAST_NAME>Deane</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Research Related to Nursing</POSITION>
<EMAIL_1>k.deane@uea.ac.uk</EMAIL_1>
<EMAIL_2>Katherine.deane@unn.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Edith Cavell Building</DEPARTMENT>
<ORGANISATION>University of East Anglia</ORGANISATION>
<ADDRESS_1>Colney Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Norwich</CITY>
<ZIP>NR4 7UL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1603 597047</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1603 597019</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-13 15:35:44 +0000" MODIFIED_BY="Ema Roque">
<UP_TO_DATE>
<DATE DAY="17" MONTH="11" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="11" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2015-12-16 10:56:48 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-12-16 10:56:48 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="12" YEAR="2015"/>
<DESCRIPTION>
<P>PLS correction</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="13" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="11" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-12-16 10:56:19 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-12-16 10:56:19 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-12-16 10:56:17 +0000" MODIFIED_BY="[Empty name]">Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease</TITLE>
<SUMMARY_BODY MODIFIED="2015-12-16 10:56:19 +0000" MODIFIED_BY="[Empty name]">
<P>In the later stages of Parkinson's disease, side effects occur because of the use of levodopa treatment. These consist of involuntary writhing movements (dyskinesia), painful cramps in the legs (dystonia) and a shortened response to each dose referred to as 'end-of-dose deterioration' or the 'wearing-off effect'. Dopamine agonist drugs act by mimicking levodopa in the brain, but they do not cause these long-term treatment complications when used as initial therapy. For this reason, dopamine agonists have for some years been added once these problems develop in the hope of improving them. Cabergoline is a new dopamine agonist recently licensed in the UK for the treatment of later Parkinson's disease. In this review, we will examine the trials performed with this drug to see how effective it is compared with the older drug bromocriptine and what side effects it causes.</P>
<P>Cabergoline has been compared with the older agonist bromocriptine in five studies including 1071 patients. Only one of the smaller studies was medium term (36 weeks), the others all being short term (12 -15 weeks). The time patients spent in the immobile off state was reduced with both agonists but slightly more by cabergoline compared with bromocriptine. This small advantage of cabergoline did not reach statistical significance. Dyskinesia reported as a side effect was significantly increased with cabergoline compared with bromocriptine. Physical impairment and disability were measured in four of the studies but no statistically significant advantage for cabergoline was found. The number of patients rated as much or very much improved on a clinician's global impression scale was similar with both agonists. Levodopa dose reduction was no different between cabergoline and bromocriptine. There was significantly more confusion with cabergoline. Otherwise, dopaminergic side effects were comparable with these agonists and no significant difference in the withdrawal rate from the trials was found.</P>
<P>Cabergoline produces similar benefits to bromocriptine in off time reduction, physical impairment and disability ratings, and levodopa dose reduction over the first three months of therapy. The frequency of side effects and withdrawals from treatment were similar with the two agonists apart from increased dyskinesia and confusion with cabergoline.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Long term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the efficacy and safety of adjuvant cabergoline therapy versus bromocriptine in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Pharmacia Upjohn Limited.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of cabergoline versus bromocriptine in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were abstracted independently by the authors and differences settled by discussion. The outcome measures used included Parkinson's disease rating scales, levodopa dosage, off time measurements and the frequency of withdrawals and adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Cabergoline has been compared with bromocriptine in five randomised, double-blind, parallel group studies including 1071 patients. Only one of the phase II studies was medium term (36 weeks), the others all being short term (12 -15 weeks). The non-significant difference in off time reduction produced by cabergoline compared with bromocriptine was 0.29 hours/day in favour of the former (weighted mean difference; 95% CI -0.10, 0.68; p = 0.15). Dyskinesia reported as an adverse event was significantly increased with cabergoline compared with bromocriptine (Peto odds ratio 1.57; 95% CI 1.05, 2.35; p = 0.03). Motor impairment and disability were measured in four of the studies using the UPDRS rating scale but the small differences in UPDRS ADL (part II) and motor (part III) scores were not statistically significant in any study. Similarly, no significant difference in Schwab and England score was seen. The number of patients rated as much or very much improved on a clinician's global impression scale was similar with both agonists. Levodopa dose reduction was no different between cabergoline and bromocriptine. There was more confusion with cabergoline (Peto odds ratio 2.02; 95% CI 1.09, 3.76; p = 0.03). Otherwise, dopaminergic adverse events were comparable with these agonists and no significant difference in all cause withdrawal rate was found.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Cabergoline produces similar benefits to bromocriptine in off time reduction, motor impairment and disability ratings, and levodopa dose reduction over the first three months of therapy. Dyskinesia and confusion were increased with cabergoline but otherwise the frequency of adverse events and withdrawals from treatment were similar with the two agonists.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<BACKGROUND>
<P>Over 20 years after its introduction, levodopa remains the most effective therapy in Parkinson's disease. However, with long-term treatment, patients develop side effects comprised of motor and psychiatric complications. The former consist of involuntary writhing movements of the limbs and trunk (choreoathetosis), painful cramps often affecting the feet (dystonia) and a shortened response to each dose of levodopa (end-of-dose deterioration). These affect 50% of patients after 6 years of therapy (<LINK REF="REF-Rajput-1984" TYPE="REFERENCE">Rajput 1984</LINK>) and 100% of young onset patients (<LINK REF="REF-Quinn-1986" TYPE="REFERENCE">Quinn 1986</LINK>).</P>
<P>An alternative treatment in Parkinson's disease is the dopamine agonist class of drug. These act directly on post-synaptic dopamine receptors in the striatum and, unlike levodopa, they do not require conversion into dopamine. They have developed the reputation of being less effective in clinical practice than expected, although they generate fewer motor complications when used as long-term monotherapy. The use of dopamine agonists in newly diagnosed patients will be the subject of further Cochrane reviews.</P>
<P>Cabergoline is an ergoline class dopamine agonist along with bromocriptine, pergolide, and lisuride. It has a long half-life of around 65 hours compared with the other dopamine agonists and thus is administered once daily. Therefore, it is easier to titrate and for the patient to take and potentially it may reduce motor complications more by reducing the phasic stimulation of dopamine receptors.</P>
<P>The efficacy and safety of cabergoline have been examined in early and advanced Parkinson's disease. Monotherapy studies will be examined in other Cochrane reviews. Trials in later disease have lead to cabergoline being licensed in the United Kingdom for this indication in the expectation of a reduction in off time and improved motor function.</P>
<P>The present systematic review examines all randomised controlled trials of adjuvant cabergoline therapy compared with bromocriptine in later Parkinson's disease with motor complications to establish its efficacy and tolerability. A separate review covers the effects of adjuvant cabergoline versus placebo.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the efficacy and safety of adjuvant cabergoline versus bromocriptine in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised trials comparing adjuvant cabergoline with bromocriptine were considered for inclusion in the study.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a clinical diagnosis of idiopathic Parkinson's disease who had developed long-term motor complications of dyskinesia and/or end-of-dose deterioration. All ages were included. Any duration of levodopa therapy was included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral cabergoline therapy or bromocriptine. Trial durations of greater than 4 weeks were included. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Improvement in the time patients spend in the immobile 'off' state.</P>
<P>2. Changes in dyskinesia rating scales and the prevalence of dyskinesia.</P>
<P>3. Changes in parkinsonian rating scales.</P>
<P>4. Reduction in levodopa dose.</P>
<P>5. Number of withdrawals due to lack of efficacy and/or side-effects.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. The review was based on the search strategy of the Movement Disorders Group. This included computerised searches of MEDLINE and EMBASE and hand searching of appropriate neurology journals. Relevant trials were included on the Group's specialised register of randomised controlled trials. Further details are available in the Group's module on the Cochrane Database of Systematic Reviews.</P>
<P>2. The Cochrane Controlled Trials Register was also searched for relevant trials.</P>
<P>3. The reference lists of located trials and of other cabergoline reviews were searched.</P>
<P>4. Additional assistance was provided by the drug manufacturer Pharmacia Upjohn.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The two authors (CC, KD) independently assessed the studies identified by the search strategy. Disagreements about inclusions were resolved by discussion. The full papers were assessed for methodological quality by recording the method of randomisation and blinding, whether an intention-to-treat analysis was used and the number of patients lost to follow up.</P>
<P>Eligible data was abstracted onto standardised forms by the authors independently, checked for accuracy and amalgamated. A weighted estimate (fixed effect model) of the typical treatment effect across trials was calculated for continuous (weighted mean difference) and dichotomous (Peto odds ratio) variables such as 'off' time and prevalence of adverse events. Since multiple comparisons of adverse events were examined statistically, the results were interpreted cautiously using 99% confidence intervals.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque">
<STUDY_DESCRIPTION MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque">
<P>See also Characteristics of Included Studies and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>Characteristics and Results of Included Studies.</P>
<P>Five trials fulfilled the inclusion criteria (<LINK REF="STD-Gershanik-1994" TYPE="STUDY">Gershanik 1994</LINK>; <LINK REF="STD-Gershanik-1994b" TYPE="STUDY">Gershanik 1994b</LINK>; <LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>; <LINK REF="STD-Korczyn-1994" TYPE="STUDY">Korczyn 1994</LINK>; <LINK REF="STD-Yanagisawa-1996" TYPE="STUDY">Yanagisawa 1996</LINK>). Only two of these studies have been published (<LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>; <LINK REF="STD-Yanagisawa-1996" TYPE="STUDY">Yanagisawa 1996</LINK> - in Japanese) but data from the other three and additional data on all trials was provided by the manufacturer. A total of 1071 patients with Parkinson's disease and motor fluctuations were included in these studies.</P>
<P>All five studies were randomised, double-blind, parallel group design. Two were phase II studies (<LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>; <LINK REF="STD-Korczyn-1994" TYPE="STUDY">Korczyn 1994</LINK>) and the remaining three phase III studies (<LINK REF="STD-Gershanik-1994" TYPE="STUDY">Gershanik 1994</LINK>; <LINK REF="STD-Gershanik-1994b" TYPE="STUDY">Gershanik 1994b</LINK>; <LINK REF="STD-Yanagisawa-1996" TYPE="STUDY">Yanagisawa 1996</LINK>). In three trials, patients only continued in the study after titration if they had responded to the trial medication, so only the data up to the end of the titration period has been included (<LINK REF="STD-Gershanik-1994" TYPE="STUDY">Gershanik 1994</LINK>; <LINK REF="STD-Gershanik-1994b" TYPE="STUDY">Gershanik 1994b</LINK>; <LINK REF="STD-Korczyn-1994" TYPE="STUDY">Korczyn 1994</LINK>).</P>
<P>Patients were well balanced across the arms of the studies in terms of age and Hoehn and Yahr score, apart from in <LINK REF="STD-Korczyn-1994" TYPE="STUDY">Korczyn 1994</LINK> where the cabergoline arm has a worse Hoehn and Yahr stage at entry (see Characteristics of Included Studies).</P>
<P>The maximum dose of cabergoline used in the trials was 4.0 - 6.0 mg/d which is broadly comparable with the present licensed limit of 6.0 mg/d. The maximum dose of bromocriptine ranged between 22.5 md/d in one trial (<LINK REF="STD-Yanagisawa-1996" TYPE="STUDY">Yanagisawa 1996</LINK>) and 40.0 mg/d in the others, the latter being comparable to clinically used doses. </P>
<P>Levodopa dose reduction was allowed in all of the trials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque">
<P>See also Characteristics of Included Studies and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>Key Characteristics and Results of Included Studies.</P>
<P>Details on randomisation and concealment of allocation were described in four of the trial reports and were found to be adequate. However, information on the other study was not available (<LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>).</P>
<P>The double-blind design of all of the trials should exclude performance and attrition bias. Detection bias is unlikely in view of the double-blind design and the use of a pre-specified statistical analysis for all studies.</P>
<P>One of the phase II studies was short term (<LINK REF="STD-Korczyn-1994" TYPE="STUDY">Korczyn 1994</LINK>, 13 weeks) whereas the other was medium term (<LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>; 36 weeks). All of the phase III studies were short term (12 -15 weeks).</P>
<P>Sample size calculations were not included in the small phase II trials which is standard practice. Such calculations were provided in all phase III study reports (<LINK REF="STD-Gershanik-1994" TYPE="STUDY">Gershanik 1994</LINK>; <LINK REF="STD-Gershanik-1994b" TYPE="STUDY">Gershanik 1994b</LINK>; <LINK REF="STD-Yanagisawa-1996" TYPE="STUDY">Yanagisawa 1996</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque">
<P>See also <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>Characteristics and Results of Included Studies and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> Adverse Events for Included Studies.</P>
<P>Cabergoline has been compared with bromocriptine in two phase II (<LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>; <LINK REF="STD-Korczyn-1994" TYPE="STUDY">Korczyn 1994</LINK>) and three phase III randomised controlled trials (<LINK REF="STD-Gershanik-1994" TYPE="STUDY">Gershanik 1994</LINK>; <LINK REF="STD-Gershanik-1994b" TYPE="STUDY">Gershanik 1994b</LINK>; <LINK REF="STD-Yanagisawa-1996" TYPE="STUDY">Yanagisawa 1996</LINK>). These were double-blind, parallel group studies including 1071 patients with Parkinson's disease and motor complications. Only one of the phase II studies was medium term (36 weeks), the others all being short term (12 -15 weeks).</P>
<P>Information on off time reduction was available expressed as hours per day in only four of the five trials (Table 7). The difference in the off time reduction produced by cabergoline compared with bromocriptine was 0.29 hours/day (weighted mean difference; 95% CI -0.10, 0.68; p = 0.15; Table 7). The difference between the agonists in off time reduction was only statistically significant for one of the small phase II studies (<LINK REF="STD-Inzelberg-1996" TYPE="STUDY">Inzelberg 1996</LINK>).</P>
<P>None of the studies used a dyskinesia rating scale. Dyskinesia reported as an adverse event was significantly increased with cabergoline compared with bromocriptine (Peto odds ratio 1.57; 95% CI 1.05, 2.35; p = 0.03; Table 12).</P>
<P>Motor impairment and disability were measured in four of the studies using the UPDRS rating scale (Tables 1 and 2). The small differences in UPDRS ADL (part II) and motor (part III) scores were not statistically significant in any study. Similarly, no significant difference in Schwab and England score was seen (Table 4). The number of patients rated as much or very much improved on a clinician's global impression scale was similar with both agonists (Table 5).</P>
<P>Levodopa dose reduction was no different between cabergoline and bromocriptine (Table 6).</P>
<P>There was significantly more confusion with cabergoline (Peto odds ratio 2.02; 95% CI 1.09, 3.76; p = 0.03; Table 11). Otherwise, dopaminergic adverse events were comparable with these agonists (Tables 8 - 10 and 12 - 16). The all cause withdrawal rate was also similar (Table 17).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<P>Cabergoline has been compared with bromocriptine in five randomised controlled trials involving 1071 patients with Parkinson's disease and motor complications. This is the largest number of patients involved in any of the placebo- or bromocriptine-controlled adjuvant therapy programmes according to previous Cochrane reviews. In spite of this, all bar one small phase II study were short term lasting for just 12 to 15 weeks. Thus, the conclusions of this review should not be extrapolated beyond this period.</P>
<P>Reducing the time patients spend in the off phase is a major goal of adjuvant therapy at this stage of the disease. Cabergoline and bromocriptine both reduced off time in these studies. Although there was a trend towards more reduction in off time with cabergoline, this did not reach statistical significance (0.29 hours/day; 95% CI -0.10, 0.68; p = 0.15). In contrast, there was increased dyskinesia reported as an adverse event in the cabergoline treated patients. No significant benefit of cabergoline over bromocriptine was found in the improvement in motor impairments and disability as measured with the UPDRS ADL and motor scales and the Schwab and England score. Similarly, levodopa dose reduction was comparable with the two agonists. There was more confusion with cabergoline but adverse events and withdrawals were otherwise similar with both agonists.</P>
<P>In summary, cabergoline produces similar benefits and hazards to bromocriptine, although these conclusions must be limited to the first three months of therapy in view of the short duration of most of the studies. Caution should be exercised in interpreting the results of this review as small but clinically relevant differences between the agonists may have been disclosed in larger trials with appropriate statistical power to avoid a false negative conclusion. Also, if larger doses of bromocriptine had been used, any differences between the agonists may have disappeared. Further trials are necessary before it can be concluded that one agonist is superior to another. In the meantime, other characteristics of these agents should be considered such as the ease of titration and administration of cabergoline versus the lower cost of bromocriptine.</P>
<P>Regarding the conduct of these five trials, a number of comments on their design and reporting should be made in the hope of improving the quality of similar work in the future:-</P>
<UL>
<LI>Only one of these studies has been published and it seems unlikely to the authors that the others will ever enter the public domain. This potentially may give rise to publication bias, so manufacturers should be encouraged to publish all such work in some form.</LI>
<LI>The standard of reporting of methods and results was better in these more recent studies than with some of the earlier agonist development programmes judging from previous Cochrane reviews. However, most were internal industry reports which are necessarily more detailed. On publication, the CONSORT reporting guidelines should be followed (<LINK REF="REF-CONSORT-1996" TYPE="REFERENCE">CONSORT 1996</LINK>).</LI>
<LI>The trials with cabergoline were similar to those with all of the other dopamine agonists in using outcomes which measured motor impairments and disability. No quality of life measures or health economics outcomes were included. Therefore, no conclusions regarding the effectiveness of these agents can be drawn. Further studies are required to examine these issues.</LI>
<LI>Further studies of adjuvant therapy in Parkinson's disease should have sufficient power to examine whether the new agonists are superior to the less expensive bromocriptine.</LI>
</UL>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<IMPLICATIONS_PRACTICE>
<P>Cabergoline produces similar benefits to bromocriptine in off time reduction, motor impairment and disability ratings, and levodopa dose reduction over the first three months of therapy. Dyskinesia and confusion were greater with cabergoline but otherwise the frequency of adverse events and withdrawals from treatment were similar with the two agonists. In view of the low power of these studies to detect small but clinically significant differences between the agonists, these results should be treated with caution. Further work is required before one agonist can be prefered over another, particularly in view of the ease of titration and administration of cabergoline and the lower cost of bromocriptine.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<P>Incomplete Reporting<BR/>
</P>
<UL>
<LI>Only one of the five studies included here has been published in a peer reviewed journal. Some mechanism must be found to ensure that such information enters the public domain to reduce the potential for publication bias.</LI>
<LI>All publications stemming from randomised controlled trials should conform to the CONSORT reporting guidelines (<LINK REF="REF-CONSORT-1996" TYPE="REFERENCE">CONSORT 1996</LINK>).</LI>
</UL>
<P>
<BR/>Further Trials<BR/>
</P>
<UL>
<LI>A further paper publication will summarise the results of all of the adjuvant therapy Cochrane reviews, but it is apparent that no one of the more recently introduced dopamine agonists is clearly superior to another or the older bromocriptine. Further large pragmatic trials are required to provide data on the comparative efficacy, effectiveness and safety of the dopamine agonists as adjuvant therapy in Parkinson's disease.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors thank Pharmacia Upjohn for their assistance in performing this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>CEC has received payment from Pharmacia Upjohn for lectures and attending meetings.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<STUDIES MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque">
<INCLUDED_STUDIES MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Gershanik-1994" MODIFIED="2008-11-13 15:37:39 +0000" MODIFIED_BY="Ema Roque" NAME="Gershanik 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Destee A, Schneider E, Gershanik O, et al</AU>
<TI>Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (not on treatment with DA-agents)</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>Supplement 1</NO>
<PG>269</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Gershanik O, Dom R, Tichy J, Ziegler M, Schneider E, Korczyn AD</AU>
<TI>Multicenter, multinational double-blind study of the activity and tolerability of cabergoline vs bromocriptine in parkinsonian patients suffering from L-dopa associated motor complications, not on treatment with dopamine agonist agents</TI>
<SO>Farmitalia Carlo Erba; Clinical Reference 40</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Gershanik-1994b" MODIFIED="2008-11-13 15:38:03 +0000" MODIFIED_BY="Ema Roque" NAME="Gershanik 1994b" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Gershnik O, Dom R, Ziegler M, Schneider E, Korczyn AD, Nappi G</AU>
<TI>Multicenter, multinational double-blind study of the activity and tolerability of cabergoline vs bromocriptine in parkinsonian patients suffering from L-dopa associated motor complications on treatment with dopamine agonist agents</TI>
<SO>Farmitalia Carlo Erba; Clincal Reference 41</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider E, Gershanik O, Dom R, et al</AU>
<TI>Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (on treatment with DA-agents)</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>Supplement 1</NO>
<PG>269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inzelberg-1996" MODIFIED="2008-11-13 15:38:13 +0000" MODIFIED_BY="Ema Roque" NAME="Inzelberg 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Inzelberg R, Nisipeanu P, Rabey JM, et al</AU>
<TI>Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<PG>785-788</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Korczyn-1994" MODIFIED="2008-11-13 15:38:20 +0000" MODIFIED_BY="Ema Roque" NAME="Korczyn 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Korczyn A, Stern G, Parkes D, et al</AU>
<TI>Multicentre, multinational double blind study of the activity and tolerability of cabergoline vs bromocriptine in Parkinsonian patients suffering fromL-dopa associated motor complications</TI>
<SO>FCE Report 21336/736i</SO>
<YR>1994</YR>
<VL>Clinical Reference 37</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Yanagisawa-1996" MODIFIED="2008-11-13 15:38:25 +0000" MODIFIED_BY="Ema Roque" NAME="Yanagisawa 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yanagisawa N, Kowa H, Mizuno Y, Kanazawa I, Ogawa N, Nakashima M.</AU>
<TI>The clinical evaluation of CG-101 (Cabergoline) in Parkinson's disease patients with L-DOPA - A multi-centred phase III double-blind comparative study VS. bromocriptine mesilate -</TI>
<SO>Journal of Clinical Therapeutics and Medicines</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>17</NO>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque">
<REFERENCE ID="REF-CONSORT-1996" MODIFIED="2008-11-13 15:38:46 +0000" MODIFIED_BY="Ema Roque" NAME="CONSORT 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF.</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement.</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-639</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quinn-1986" NAME="Quinn 1986" TYPE="JOURNAL_ARTICLE">
<AU>Quinn N, Critchley P, Parkes D, Marsden CD</AU>
<TI>When should levodopa be started?</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>ii</VL>
<PG>985-986</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajput-1984" NAME="Rajput 1984" TYPE="JOURNAL_ARTICLE">
<AU>Rajput AH, Stern W, Laverty WH</AU>
<TI>Chronic low-dose levodopa therapy in Parkinson's disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>991-996</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Gershanik-1994">
<CHAR_METHODS>
<P>Randomised, double blind, parallel group design.<BR/>Computerised randomisation list generated. Treatments were balanced within blocks of 4 patients.<BR/>Intention to treat analysis only for clinicians global impression score, all other data analysed on a per protocol basis.<BR/>Location: 69 sites in 13 countries<BR/>Duration: Titration phase of 15 weeks maximum (mean 10 weeks), if the patients showed minimal improvement or better there followed a 3 month stable dose phase. Patients in whom improvement was maintained entered a follow-up treatment period (mean 10 months) carried out in double-blind conditions until completion of last patient in each country, and subsequently in open conditions. Median duration, cabergoline = 444 days, bromocriptine = 455 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Cabergoline: 191 patients with 28 drop-outs (15%) at the end of the titration phase.<BR/>Bromocriptine: 193 patients with 34 drop-outs (18%) at the end of the titration phase.<BR/>Age: Cabergoline = 62.3 years (SD9.1), Bromocriptine = 61.7 years (SD8.4)<BR/>Hoehn and Yahr scale at baseline: 2 or 2.5 in 111/191 of the patients in the cabergoline group, 123/193 in the bromocriptine group.<BR/>Inclusion criteria: IPD with motor fluctuations<BR/>Exclusion criteria: history of intolerance of dopamine agonists, severe depression, other CNS disorders, serious cardiac disease, kidney or liver impairment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drugs titrated over 15 weeks, 8 dose levels, increments applied at weekly/biweekly intervals.<BR/>Cabergoline: initial dose = 0.5mg/d, maximum = 6mg/d, median = 4mg/d.<BR/>Bromocriptine: initial dose = 5mg/d, maximum = 40mg/d, median = 25mg/d.<BR/>Levodopa could be reduced.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Clinicians global impression scale (7 points).<BR/>Secondary: Off hours<BR/>UPDRS<BR/>Hoehn and Yahr<BR/>Schwab and England<BR/>Adverse Events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only data from the end of titration phase was used in this review as patients were subsequently selected for on the basis of their response to the drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gershanik-1994b">
<CHAR_METHODS>
<P>Randomised, double blind, parallel group design.<BR/>Intention to treat analysis only for clinicians global impression score, all other data analysed on a per protocol basis.<BR/>Location: 67 sites throughout Europe, Israel and Latin America.<BR/>Duration: Titration phase 13 weeks maximum (mean 2 months), if the patients showed minimal improvement or better there followed a 3 month stable dose phase. Patients in whom improvement was maintained entered a follow-up treatment period carried out in double-blind conditions until completion of last patient in each country, and subsequently in open conditions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Cabergoline: 181 patients with 23 drop-outs (13%) after titration phase.<BR/>Bromocriptine: 185 patients with 21 drop-outs (11%) after titration phase.<BR/>Age: Cabergoline = 61.0 years (SD9.8), Bromocriptine = 60.9 years (SD9.3).<BR/>Hoehn and Yahr score at baseline, 'On' state: cabergoline 2.1, bromocriptine 2.1; 'Off' state: cabergoline 3.4, bromocriptine 3.5.<BR/>Inclusion criteria: IPD with motor fluctuations<BR/>Exclusion criteria: History of intolerance of dopamine agonists, severe depression, other CNS disorders, serious cardiac disease, liver or renal impairment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drugs titrated over 15 weeks, 8 dose levels, increments applied at weekly/biweekly intervals.<BR/>Cabergoline: initial dose = 0.5mg/d, maximum = 6mg/d, mean 4.4mg/d.<BR/>Bromocriptine: initial dose = 5mg/d, maximum = 40mg/d, mean 28.7 mg/d<BR/>Levodopa could be reduced.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Clinicians global impression score (7 points)<BR/>Secondary: Off/On diaries<BR/>UPDRS<BR/>Hoehn and Yahr<BR/>Schwab and England<BR/>Adverse Events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only data from the end of titration phase was used in this review as patients were subsequently selected for on the basis of their response to the drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Inzelberg-1996">
<CHAR_METHODS>
<P>Randomised, double blind, parallel group design.<BR/>Randomisation method not stated.<BR/>Analysis not intention to treat. All follow-up visit results included in calculating 'mean' response to treatment then this was compared with 'baseline' values.<BR/>Location: 1 site in Israel.<BR/>Duration: Variable titration phase followed by 6-12 month stable dose phase. Mean duration 9 months (SD5).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Cabergoline: 22 patients with 7 drop-outs (32%).<BR/>Bromocriptine: 22 patients with 12 drop-outs (55%).<BR/>Details of terminations given. Withdrawals allowed due to lack of efficacy.<BR/>Mean age 71 years (SD8).<BR/>Hoehn and Yahr score at baseline: Stage II or III when 'on'. No means given.<BR/>Inclusion criteria: IPD with motor complications.<BR/>Exclusion criteria: history of severe psychiatric disturbances with dopamine agonists, severe depression, serious heart disease, renal or liver impairment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cabergoline: Initial dose 0.5mg/d, increased every two weeks by 0.25mg/d or 0.5mg/d, maximum dose 6mg/d, mean dose 3.2mg/d.<BR/>Bromocriptine: Initial dose 5mg/d, increased every two weeks by 2.5mg/d or 5mg/d, maximum dose 40mg, mean dose 22.1mg/d<BR/>Levodopa could be reduced</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>UPDRS ADL subsection<BR/>UPDRS motor subsection<BR/>Items of motor UPDRS (tremor, rigidity etc)<BR/>Dyskinesia (UPDRS item 32)<BR/>Schwab and England<BR/>On/Off charts<BR/>Adverse Events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Korczyn-1994">
<CHAR_METHODS>
<P>Randomised, double-blind, parallel group design. <BR/>A computerized randomisation list was generated. Treatments were balanced within blocks of 4 cases. The study medication was prepared and labelled with corresponding patient numbers. In each centre patients were to recieve progressive randomisation numbers according to theri temporal entry into the study.<BR/>Data analysed on a per protocol basis.<BR/>Location: 12 sites.<BR/>Duration: Titration phase of 13 weeks, if the patients showed minimal improvement or better there followed a 3 month stable dose phase.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Cabergoline: 22 patients with 3 drop-outs (14%) at end of titration phase.<BR/>Bromocriptine: 20 patients with 5 drop-outs (25%) at end of titration phase.<BR/>Age: Cabergoline = 61.4 years (SD 6.4), Bromocriptine = 59.6 years (SD 9.6)<BR/>Hoehn and Yahr at baseline, 'On' state: Cabergoline 2.3, Bromocriptine 2.5, 'Off' state: Cabergoline 3.2, bromocriptine 3.4.<BR/>Inclusion criteria: IPD with motor fluctuations. Other dopamine agonists stopped 2 weeks prior to trial.<BR/>Exclusion criteria: Other CNS degenerative disorders, severe depression or dementia, cardiopathies, history of severe psychiatric disorder with previous dopamine agonists, renal or hepatic impairment, child bearing potential.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Drugs titrated over 13 weeks, increments applied at weekly/fortnightly intervals.<BR/>Cabergoline: initial dose = 0.5mg/d, maximum = 4.0mg/d<BR/>Bromocriptine: initial dose = 5.0mg/d, maximum = 40mg/d<BR/>Levodopa could be reduced.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Clinicians Global Impression score (7 points)<BR/>Secondary: Off hours<BR/>UPDRS parts II and III<BR/>Hoehn and Yahr<BR/>Swab and England<BR/>Adverse Events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only data from the end of the titration phase was used in this review as patients were subsequently selected on the basis of their response to the drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yanagisawa-1996">
<CHAR_METHODS>
<P>Randomised double blind parallel group design.<BR/>A computerized randomisation list was generated.<BR/>Treatments were balanced within blocks of 4 cases. Data analysed on a per protocol basis. Intention to treat analysis claimed for primary outcomes but 2 patients in bromocriptine group that withdrew consent before the start of the therapy were excluded.<BR/>Location: Multicentre, Japan.<BR/>Duration: 12 weeks (including 8 week titration phase).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Cabergoline: 115 patients with 26 drop-outs (23%).<BR/>Bromocriptine: 120 patients with 27 drop-outs (23%).<BR/>Age: Cabergoline = 65.8 years (SD8.9), bromocriptine = 64.2 years (SD8.7).<BR/>Hoehn &amp; Yahr at baseline, 'On' state: Cabergoline 2.7, bromocriptine 2.8, (32 drop-outs not characterised).<BR/>Inclusion criteria: PD, over 20 years old, on l-dopa with motor fluctuations or on l-dopa &amp; obtaining therapeutic effect but desiring further improvement.<BR/>Exclusion criteria: Ever recieved cabergoline, on other ergot derivatives (but could be included after 1 month wash-out period). Hypersensitive to ergot derivative. Patients with complications of PD other than IPD. Patients with conciousness disturbance, severe hypotension or organ dysfunction. Peripheral vascular lesions, active peptic ulcer, childbearing potential.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cabergoline: Initial dose 0.25mg/d, increased weekly to maximum 4.0mg/d. Mean dose 2.74 mg/d.<BR/>Bromocriptine: Initial dose 1.25mg/d increased weekly to maximum 22.5mg/d. Mean dose 16.44mg/d.<BR/>Levodopa could be reduced.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Improvement of neurological symptoms<BR/>Final Global Improvement<BR/>Overall safety<BR/>Usefulness<BR/>Secondary: Levodopa reduction<BR/>Off hours reduction<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gershanik-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gershanik-1994b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Inzelberg-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Korczyn-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yanagisawa-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Key Characteristics and Results for Included Studies</TITLE>
<TABLE COLS="10" ROWS="8">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Study</P>
</TD>
<TD>
<P>Number of patients</P>
</TD>
<TD>
<P>Mean Hoehn &amp; Yahr</P>
</TD>
<TD>
<P>Duration (weeks)</P>
</TD>
<TD>
<P>Mean (Maximum) dose Cabergoline / Bromocriptine (mg/d)</P>
</TD>
<TD>
<P>Mean difference (MD) L-dopa reduction mg/d; + in favour of cabergoline)</P>
</TD>
<TD>
<P>MD off hours reduction (hours; + in favour of cabergoline)</P>
</TD>
<TD>
<P>MD UPDRS ADL (+ in favour of cabergoline)</P>
</TD>
<TD>
<P>MD UPDRS Motor (+ in favour of cabergoline)</P>
</TD>
<TD>
<P>Drop-outs (Peto Odds Ratio &lt; 1 in favour of cabergoline)</P>
</TD>
</TR>
<TR>
<TD>
<P>Korczyn</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>n/a (4.0) / n/a (40)</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>1.0 (off) -0.5 (on)</P>
</TD>
<TD>
<P>0 (on)</P>
</TD>
<TD>
<P>0.49</P>
</TD>
</TR>
<TR>
<TD>
<P>Gershanik 40</P>
</TD>
<TD>
<P>384</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>Median 4.0 (6.0)/ 25 (40.0)</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>0.8 (off) -0.3 (on)</P>
</TD>
<TD>
<P>-0.8 (off) 1.7 (on)</P>
</TD>
<TD>
<P>0.80</P>
</TD>
</TR>
<TR>
<TD>
<P>Gershanik 41</P>
</TD>
<TD>
<P>366</P>
</TD>
<TD>
<P>3.5 (off) 2.1 (on)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>4.4 (6.0)/ 28.7 (40.0)</P>
</TD>
<TD>
<P>-2.8</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>0.6 (off) 0.2 (on)</P>
</TD>
<TD>
<P>1.9 (off) 0.2 (on)</P>
</TD>
<TD>
<P>1.14</P>
</TD>
</TR>
<TR>
<TD>
<P>Inzelberg</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>3.2 (6.0)/ 22.1 (40.0)</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>1.76</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-2</P>
</TD>
<TD>
<P>0.40</P>
</TD>
</TR>
<TR>
<TD>
<P>Yanagisawa</P>
</TD>
<TD>
<P>235</P>
</TD>
<TD>
<P>2.8 (on)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>2.7 (4.0)/ 16.4 (22.5)</P>
</TD>
<TD>
<P>7.3</P>
</TD>
<TD>
<P>-0.91</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>1.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Total/Mean</P>
</TD>
<TD>
<P>1071</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6.0 (WMD)</P>
</TD>
<TD>
<P>0.38 (WMD)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.87</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Adverse Events for Included Studies (Peto Odds Ratio &lt; 1 favours cabergoline)</TITLE>
<TABLE COLS="10" ROWS="9">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Study (number)</P>
</TD>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>Postural Hypotension</P>
</TD>
<TD>
<P>Hallucinations</P>
</TD>
<TD>
<P>Confusion</P>
</TD>
<TD>
<P>Dyskinesia</P>
</TD>
<TD>
<P>Insomnia</P>
</TD>
<TD>
<P>Sleep disorder</P>
</TD>
<TD>
<P>Vivid Dreams</P>
</TD>
<TD>
<P>Somnolence</P>
</TD>
</TR>
<TR>
<TD>
<P>Korczyn (42)</P>
</TD>
<TD>
<P>0.88</P>
</TD>
<TD>
<P>0.89</P>
</TD>
<TD>
<P>1.83</P>
</TD>
<TD>
<P>1.83</P>
</TD>
<TD>
<P>1.40</P>
</TD>
<TD>
<P>0.45</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>0.64</P>
</TD>
</TR>
<TR>
<TD>
<P>Gershanik 40 (384)</P>
</TD>
<TD>
<P>0.98</P>
</TD>
<TD>
<P>1.07</P>
</TD>
<TD>
<P>1.36</P>
</TD>
<TD>
<P>1.69</P>
</TD>
<TD>
<P>1.93</P>
</TD>
<TD>
<P>1.38</P>
</TD>
<TD>
<P>2.06</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>2.24</P>
</TD>
</TR>
<TR>
<TD>
<P>Gershanik 41 (366)</P>
</TD>
<TD>
<P>0.83</P>
</TD>
<TD>
<P>0.45</P>
</TD>
<TD>
<P>1.43</P>
</TD>
<TD>
<P>2.38</P>
</TD>
<TD>
<P>1.48</P>
</TD>
<TD>
<P>0.79</P>
</TD>
<TD>
<P>1.02</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>0.56</P>
</TD>
</TR>
<TR>
<TD>
<P>Inzelberg (44)</P>
</TD>
<TD>
<P>2.01</P>
</TD>
<TD>
<P>1.82</P>
</TD>
<TD>
<P>0.12</P>
</TD>
<TD>
<P>2.01</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>0.30</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>Yanagisawa (235)</P>
</TD>
<TD>
<P>1.28</P>
</TD>
<TD>
<P>0.53</P>
</TD>
<TD>
<P>1.86</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>1.05</P>
</TD>
<TD>
<P>7.75</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>n/a</P>
</TD>
<TD>
<P>1.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Total/Mean (1071)</P>
</TD>
<TD>
<P>0.99</P>
</TD>
<TD>
<P>0.74</P>
</TD>
<TD>
<P>1.34</P>
</TD>
<TD>
<P>2.02</P>
</TD>
<TD>
<P>1.57</P>
</TD>
<TD>
<P>0.95</P>
</TD>
<TD>
<P>1.35</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>0.97</P>
</TD>
</TR>
<TR>
<TD>
<P>P value (Test for overall effect)</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>0.15</P>
</TD>
<TD>
<P>0.17</P>
</TD>
<TD>
<P>0.03</P>
</TD>
<TD>
<P>0.03</P>
</TD>
<TD>
<P>0.80</P>
</TD>
<TD>
<P>0.20</P>
</TD>
<TD>
<P>null</P>
</TD>
<TD>
<P>0.90</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Cabergoline versus Bromocriptine</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>UPDRS ADL scores (part II)</NAME>
<TR>
<TH/>
</TR>
<OTHER_DATA ORDER="1" STUDY_ID="STD-Gershanik-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline -6.1 (SD5.3) v bromocriptine -5.3 (SD5.6)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline -2.9 (SD3.9) v bromocriptine -3.2 (SD3.9)<BR/>p &gt; 0.05; NS.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="2" STUDY_ID="STD-Gershanik-1994b">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline -4.7 (SD5.4) v bromocriptine -4.1 (SD4.5)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline -2.9 (SD3.9) v bromocriptine -2.7 (SD3.8)<BR/>p &gt; 0.05; NS.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="3" STUDY_ID="STD-Inzelberg-1996">
<TR>
<TD>
<P>Improvement on Cabergoline (n=22) -2 (SD 5.1) v bromocriptine (n=22) -2 (SD 5.0)<BR/>p &gt; 0.05; NS.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="4" STUDY_ID="STD-Korczyn-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline (n=10) -3.9 (SD 7.9) v bromocriptine (n=10) -2.9 (SD 5.0)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline (n=16) -0.5 (SD 4.4) v bromocriptine (n=15) -1.0 (SD 3.4)<BR/>p &gt; 0.05; NS.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>UPDRS motor scores (part III)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="5" STUDY_ID="STD-Gershanik-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline -12.5 (SD 11) v bromocriptine -13.3 (SD10.1)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline -9.0 (SD8.9) v bromocriptine -7.3 (SD8.4)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="6" STUDY_ID="STD-Gershanik-1994b">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline -11.1 (SD11.3) v bromocriptine -9.2 (SD8.5)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline -6.1 (SD8.7) v bromocriptine -5.9 (SD7.9)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="7" STUDY_ID="STD-Inzelberg-1996">
<TR>
<TD>
<P>Improvement on cabergoline (n=22) -7 (SD 12.6) v bromocriptine (n=22) -9 (SD 12.7)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="8" STUDY_ID="STD-Korczyn-1994">
<TR>
<TD>
<P>'On' state: Improvement on cabergoline (n=16) -6.0 (SD 10.8) v bromocriptine (n=14) -6.0 (SD 7.9)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Hoehn and Yahr stage</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="9" STUDY_ID="STD-Gershanik-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline -0.5 (SD 0.6) v bromocriptine -0.6 (SD 0.7)<BR/>'On' state: Improvement on cabergoline -0.2 (SD 0.4) v bromocriptine -0.3 (SD 0.5)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="10" STUDY_ID="STD-Gershanik-1994b">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline -0.5 (SD 0.7) v bromocriptine -0.4 (SD 0.6)<BR/>'On' state: Improvement on cabergoline -0.1 (SD 0.5) v bromocriptine -0.2 (SD 0.5)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="11" STUDY_ID="STD-Inzelberg-1996">
<TR>
<TD>
<P>Not available</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="12" STUDY_ID="STD-Korczyn-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline (n=17) -0.38 (SD 0.81) v bromocriptine (n=15) -0.23 (SD 1.02).<BR/>'On' state: Improvement on cabergoline (n=19) -0.16 (SD 0.55) v bromocriptine (n=15) -0.30 (SD 0.72).</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Schwab and England scale</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="13" STUDY_ID="STD-Gershanik-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline 11.7 (SD 13.6) v bromocriptine 12.8 (SD 14.5)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline 5.7 (SD 7.5) v bromocriptine 6.1 (SD 9.5)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="14" STUDY_ID="STD-Gershanik-1994b">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline 9.9 (SD 14.4) v bromocriptine 8.5 (SD 12.9)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline 3.0 (SD 9.7) v bromocriptine 3.5 (SD 8.6)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="15" STUDY_ID="STD-Inzelberg-1996">
<TR>
<TD>
<P>Improvement on cabergoline (n=22) 1 (SD 10.2) v bromocriptine (n=22) -2 (SD 9.5)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="16" STUDY_ID="STD-Korczyn-1994">
<TR>
<TD>
<P>'Off' state: Improvement on cabergoline (n=18) 7.78 (SD 19.29) v bromocriptine (n=15) 6.67 (SD 22.72)<BR/>p &gt; 0.05; NS.<BR/>'On' state: Improvement on cabergoline (n=18) -0.55 (SD 11.83) v bromocriptine (n=15) 3.33 (SD 12.55)<BR/>p &gt; 0.05; NS.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.2199654789701384" CI_END="1.3315871618243929" CI_START="0.7594921088442355" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.005649015135956" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="209" I2="9.908508986012807" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.12436959935959113" LOG_CI_START="-0.11947673411614956" LOG_EFFECT_SIZE="0.00244643262172079" METHOD="PETO" NO="5" P_CHI2="0.3295649359624515" P_Q="1.0" P_Z="0.9686293700876458" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="393" TOTAL_2="391" WEIGHT="99.99999999999997" Z="0.03932738918671218">
<NAME>Clinicians global impression (number much or very much improved)</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursBromocriptine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cabergoline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8418204715176563" CI_START="0.8235245371830631" EFFECT_SIZE="1.2315779924068426" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="102" LOG_CI_END="0.26524729576907297" LOG_CI_START="-0.0843234563552478" LOG_EFFECT_SIZE="0.0904619197069126" ORDER="32172" O_E="4.940104166666671" SE="0.2053395902009566" STUDY_ID="STD-Gershanik-1994" TOTAL_1="193" TOTAL_2="191" VAR="23.716719549636686" WEIGHT="48.65889942710573"/>
<DICH_DATA CI_END="1.2932225581196497" CI_START="0.5703917897110405" EFFECT_SIZE="0.8588617638599108" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="97" LOG_CI_END="0.11167327155152006" LOG_CI_START="-0.2438267343989192" LOG_EFFECT_SIZE="-0.06607673142369958" ORDER="32173" O_E="-3.4890710382513674" SE="0.20882246324869835" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="22.93219210806084" WEIGHT="47.049307434522234"/>
<DICH_DATA CI_END="2.209417467902119" CI_START="0.14696792376785758" EFFECT_SIZE="0.5698363782648591" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3442777832668853" LOG_CI_START="-0.8327774411069337" LOG_EFFECT_SIZE="-0.24424982892002423" ORDER="32174" O_E="-1.1764705882352935" SE="0.6914080653145108" STUDY_ID="STD-Korczyn-1994" TOTAL_1="19" TOTAL_2="15" VAR="2.091852783894306" WEIGHT="4.291793138372016"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.13272643937765294" CI_END="33.786951969143736" CI_START="-21.791511292986854" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="5.997720338078443" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.9876397307680039" P_Q="1.0" P_Z="0.6722828995710238" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="456" TOTAL_2="453" UNITS="" WEIGHT="99.99999999999999" Z="0.4230169444064801">
<NAME>Levodopa dose reduction (mg)</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursBromocriptine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cabergoline</GRAPH_LABEL_2>
<CONT_DATA CI_END="74.3282323348062" CI_START="-49.1282323348062" EFFECT_SIZE="12.600000000000001" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="21.4" ORDER="32175" SD_1="269.1" SD_2="304.9" SE="31.494574809389672" STUDY_ID="STD-Gershanik-1994" TOTAL_1="169" TOTAL_2="165" WEIGHT="20.266810014684506"/>
<CONT_DATA CI_END="57.440063517714364" CI_START="-63.04006351771436" EFFECT_SIZE="-2.799999999999997" ESTIMABLE="YES" MEAN_1="18.1" MEAN_2="20.9" ORDER="32176" SD_1="273.78" SD_2="288.73" SE="30.73529105273377" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="165" TOTAL_2="170" WEIGHT="21.28051996661547"/>
<CONT_DATA CI_END="123.92430530185719" CI_START="-117.92430530185719" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="64.0" ORDER="32177" SD_1="220.0" SD_2="188.0" SE="61.69720783427281" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" WEIGHT="5.2811180481784765"/>
<CONT_DATA CI_END="45.4098176212291" CI_START="-30.809817621229104" EFFECT_SIZE="7.3" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="4.7" ORDER="32178" SD_1="145.3" SD_2="126.6" SE="19.444141791295394" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="100" TOTAL_2="96" WEIGHT="53.17155197052155"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0824326914471454" CI_END="0.6820072472143694" CI_START="-0.10475471637695416" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2886262654187077" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.7813165327096765" P_Q="1.0" P_Z="0.1504230670060007" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="300" TOTAL_2="312" UNITS="" WEIGHT="100.0" Z="1.4380387242686068">
<NAME>Off time reduction (hours)</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursBromocriptine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cabergoline</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8375717015774461" CI_START="-0.23757170157744645" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.2" ORDER="32179" SD_1="2.18" SD_2="2.31" SE="0.2742763162066973" STUDY_ID="STD-Gershanik-1994" TOTAL_1="131" TOTAL_2="137" WEIGHT="53.54931528962384"/>
<CONT_DATA CI_END="0.9273594713273486" CI_START="-0.32735947132734855" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.8" ORDER="32180" SD_1="2.99" SD_2="2.48" SE="0.3200872446003498" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="143" TOTAL_2="154" WEIGHT="39.318215786826144"/>
<CONT_DATA CI_END="2.5234796697915574" CI_START="-1.1234796697915572" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="1.7" ORDER="32181" SD_1="2.6" SD_2="2.4" SE="0.9303638659561768" STUDY_ID="STD-Korczyn-1994" TOTAL_1="16" TOTAL_2="13" WEIGHT="4.653983813270993"/>
<CONT_DATA CI_END="1.588735015888438" CI_START="-3.4087350158884373" EFFECT_SIZE="-0.9099999999999997" ESTIMABLE="YES" MEAN_1="1.37" MEAN_2="2.28" ORDER="32182" SD_1="2.27" SD_2="2.98" SE="1.2748882303951197" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="10" TOTAL_2="8" WEIGHT="2.4784851102790255"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.275806553092239" CI_END="1.351003838373031" CI_START="0.7270525665224954" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.991085671408307" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.1306565829094168" LOG_CI_START="-0.1384341881432429" LOG_EFFECT_SIZE="-0.0038888026169130742" METHOD="PETO" NO="8" P_CHI2="0.8654667595514718" P_Q="1.0" P_Z="0.9548244957496003" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="528" WEIGHT="99.99999999999999" Z="0.0566493829745143">
<NAME>Adverse events - Nausea</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5606012649365901" CI_START="0.6138713387731123" EFFECT_SIZE="0.9787790290957592" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.1932919545946121" LOG_CI_START="-0.21192264305439545" LOG_EFFECT_SIZE="-0.00931534422989169" ORDER="32183" O_E="-0.3785900783289833" SE="0.23802506050363528" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="17.650403234052998" WEIGHT="44.09886803759124"/>
<DICH_DATA CI_END="1.46945621061886" CI_START="0.4674762767352525" EFFECT_SIZE="0.8288159736428815" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.1671566487482366" LOG_CI_START="-0.3302404236029951" LOG_EFFECT_SIZE="-0.08154188742737926" ORDER="32184" O_E="-2.199453551912569" SE="0.29217350245433077" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="11.714354069236393" WEIGHT="29.267872659601156"/>
<DICH_DATA CI_END="20.42787799633612" CI_START="0.19819050732593232" EFFECT_SIZE="2.012116175494374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.310223255406519" LOG_CI_START="-0.7029171506312399" LOG_EFFECT_SIZE="0.3036530523876395" ORDER="32185" O_E="0.5" SE="1.1825286397123063" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="0.7151162790697674" WEIGHT="1.7866911029765455"/>
<DICH_DATA CI_END="3.605329239358063" CI_START="0.21718291204874127" EFFECT_SIZE="0.8848818582716325" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5569449307218669" LOG_CI_START="-0.6631743480283158" LOG_EFFECT_SIZE="-0.05311470865322441" ORDER="32186" O_E="-0.23809523809523814" SE="0.716704104025694" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="1.9467949781538632" WEIGHT="4.863993966563831"/>
<DICH_DATA CI_END="2.5544114131233946" CI_START="0.6387387866479073" EFFECT_SIZE="1.2773416326958122" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.4072908459657129" LOG_CI_START="-0.19467671102894732" LOG_EFFECT_SIZE="0.1063070674683828" ORDER="32187" O_E="1.95774647887324" SE="0.3535987227661279" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="104" TOTAL_2="109" VAR="7.9979488945365" WEIGHT="19.98257423326722"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.943507724186135" CI_END="1.1140024148773646" CI_START="0.4856872990597549" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7355656490265378" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="57" I2="19.08579447686547" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.046886132280059466" LOG_CI_START="-0.3136432533735462" LOG_EFFECT_SIZE="-0.13337856054674338" METHOD="PETO" NO="9" P_CHI2="0.2931432868616669" P_Q="1.0" P_Z="0.14700690370982117" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="528" WEIGHT="100.00000000000001" Z="1.450185118794061">
<NAME>Adverse events - Postural hypotension</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.101338063558408" CI_START="0.5424352459314805" EFFECT_SIZE="1.0676328157618076" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.3224959273831892" LOG_CI_START="-0.2656520989783198" LOG_EFFECT_SIZE="0.028421914202434624" ORDER="32188" O_E="0.5483028720626635" SE="0.3454810620644351" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="8.37821513542256" WEIGHT="37.57578385656102"/>
<DICH_DATA CI_END="0.8619985147226913" CI_START="0.2354822642767766" EFFECT_SIZE="0.4505389684035307" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="28" LOG_CI_END="-0.06449348249117468" LOG_CI_START="-0.6280417968866148" LOG_EFFECT_SIZE="-0.3462676396888948" ORDER="32189" O_E="-7.275956284153004" SE="0.33103106948502803" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="9.12562221412306" WEIGHT="40.92785901674336"/>
<DICH_DATA CI_END="8.263807273643174" CI_START="0.3995401708935885" EFFECT_SIZE="1.8170643825530985" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.91718018012709" LOG_CI_START="-0.3984395489648725" LOG_EFFECT_SIZE="0.2593703155811088" ORDER="32190" O_E="1.0" SE="0.7728015412913087" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="1.6744186046511627" WEIGHT="7.509665311381778"/>
<DICH_DATA CI_END="4.089896052953505" CI_START="0.19422588170510907" EFFECT_SIZE="0.8912708157272625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6117122703050499" LOG_CI_START="-0.7116928983581784" LOG_EFFECT_SIZE="-0.04999031402656422" ORDER="32191" O_E="-0.1904761904761907" SE="0.7773747470340178" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="1.6547757314307838" WEIGHT="7.421568223097406"/>
<DICH_DATA CI_END="2.6776111158653264" CI_START="0.10487358748990765" EFFECT_SIZE="0.5299157325685392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4277475022885287" LOG_CI_START="-0.9793338755026462" LOG_EFFECT_SIZE="-0.27579318660705876" ORDER="32192" O_E="-0.9295774647887325" SE="0.8265265664796889" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="104" TOTAL_2="109" VAR="1.4638155801671577" WEIGHT="6.56512359221645"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.479734237916678" CI_END="2.0550629045342528" CI_START="0.8798850870800561" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3447004137394745" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="41" I2="10.708988802420134" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.31282511997072354" LOG_CI_START="-0.05557404297000409" LOG_EFFECT_SIZE="0.12862553850035968" METHOD="PETO" NO="10" P_CHI2="0.344957357754923" P_Q="1.0" P_Z="0.1711143676171617" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="528" WEIGHT="99.99999999999997" Z="1.3686318988370567">
<NAME>Adverse events - Hallucinations</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.667891989222335" CI_START="0.6886843542165815" EFFECT_SIZE="1.3554834826426971" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.42616824299778405" LOG_CI_START="-0.161979783363725" LOG_EFFECT_SIZE="0.13209422981702956" ORDER="32193" O_E="2.5483028720626635" SE="0.3454810620644351" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="8.37821513542256" WEIGHT="39.234125909354084"/>
<DICH_DATA CI_END="2.7628595903331314" CI_START="0.74419265441633" EFFECT_SIZE="1.4339106709658127" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.44135881445216346" LOG_CI_START="-0.12831462101456326" LOG_EFFECT_SIZE="0.1565220967188001" ORDER="32194" O_E="3.218579234972676" SE="0.33462899592214007" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="8.93044005044388" WEIGHT="41.82012561168043"/>
<DICH_DATA CI_END="1.2462668576636833" CI_START="0.012091234382159605" EFFECT_SIZE="0.12275546700138912" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.09561104585596093" LOG_CI_START="-1.9175293601817978" LOG_EFFECT_SIZE="-0.9109591571629185" ORDER="32195" O_E="-1.5" SE="1.1825286397123063" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="0.7151162790697674" WEIGHT="3.3487994375113384"/>
<DICH_DATA CI_END="18.63812710617762" CI_START="0.1788847522139466" EFFECT_SIZE="1.8259454397984143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2704022691596788" LOG_CI_START="-0.7474266762663924" LOG_EFFECT_SIZE="0.2614877964466432" ORDER="32196" O_E="0.4285714285714286" SE="1.1852827109576451" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="0.7117969138875063" WEIGHT="3.3332552685690366"/>
<DICH_DATA CI_END="6.253933956764301" CI_START="0.5548455060112223" EFFECT_SIZE="1.8627847838120362" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7961532906638258" LOG_CI_START="-0.255827927196613" LOG_EFFECT_SIZE="0.2701626817336064" ORDER="32197" O_E="1.629107981220657" SE="0.6179389747622338" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="104" TOTAL_2="109" VAR="2.6188391458385056" WEIGHT="12.263693772885087"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2553798337691219" CI_END="3.7612773488348714" CI_START="1.0895063294413" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0243358116527466" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.5753353585826041" LOG_CI_START="0.03722975760517072" LOG_EFFECT_SIZE="0.3062825580938874" METHOD="PETO" NO="11" P_CHI2="0.9681895834332243" P_Q="1.0" P_Z="0.02566980979825545" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="419" WEIGHT="100.0" Z="2.2311709146546916">
<NAME>Adverse events - Confusion</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.598299856271833" CI_START="0.6225465906573349" EFFECT_SIZE="1.691938503120649" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6625972883073569" LOG_CI_START="-0.2058281409258437" LOG_EFFECT_SIZE="0.22838457369075663" ORDER="32198" O_E="2.02088772845953" SE="0.5101173959067865" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="3.8429057393533257" WEIGHT="38.3945835251962"/>
<DICH_DATA CI_END="5.855687895503532" CI_START="0.9673173630093158" EFFECT_SIZE="2.379980792713262" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7675779210433737" LOG_CI_START="-0.01443101672220066" LOG_EFFECT_SIZE="0.3765734521605865" ORDER="32199" O_E="4.109289617486338" SE="0.45935592105017115" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="4.739159904069912" WEIGHT="47.349085071936344"/>
<DICH_DATA CI_END="20.42787799633612" CI_START="0.19819050732593232" EFFECT_SIZE="2.012116175494374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.310223255406519" LOG_CI_START="-0.7029171506312399" LOG_EFFECT_SIZE="0.3036530523876395" ORDER="32200" O_E="0.5" SE="1.1825286397123063" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="0.7151162790697674" WEIGHT="7.144747638694885"/>
<DICH_DATA CI_END="18.63812710617762" CI_START="0.1788847522139466" EFFECT_SIZE="1.8259454397984143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2704022691596788" LOG_CI_START="-0.7474266762663924" LOG_EFFECT_SIZE="0.2614877964466432" ORDER="32201" O_E="0.4285714285714286" SE="1.1852827109576451" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="0.7117969138875063" WEIGHT="7.1115837641725825"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0877328412594756" CI_END="2.3494412960037616" CI_START="1.0500806437680856" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5707013811043" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.37096459805437787" LOG_CI_START="0.021222653163839773" LOG_EFFECT_SIZE="0.1960936256091088" METHOD="PETO" NO="12" P_CHI2="0.8962136192788098" P_Q="1.0" P_Z="0.027961314686238102" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="528" WEIGHT="100.0" Z="2.1978287100337583">
<NAME>Adverse event - Dyskinesia</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5970691502888257" CI_START="1.0383946565866693" EFFECT_SIZE="1.932660700959345" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" LOG_CI_END="0.5559487868038302" LOG_CI_START="0.016362444651888387" LOG_EFFECT_SIZE="0.28615561572785925" ORDER="32202" O_E="6.558746736292427" SE="0.3169556883755215" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="9.954120622541566" WEIGHT="42.01201818211046"/>
<DICH_DATA CI_END="2.7959256399930297" CI_START="0.7844008871349163" EFFECT_SIZE="1.4809208460865797" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.44652561679819935" LOG_CI_START="-0.10546192382936706" LOG_EFFECT_SIZE="0.17053184648441616" ORDER="32203" O_E="3.7349726775956285" SE="0.32424021374702594" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="9.5118774432987" WEIGHT="40.14550187275497"/>
<DICH_DATA CI_END="3.36838127188506" CI_START="0.2968785061081777" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5274212440224078" LOG_CI_START="-0.5274212440224078" LOG_EFFECT_SIZE="0.0" ORDER="32204" O_E="0.0" SE="0.6196196990320526" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="2.604651162790698" WEIGHT="10.993100863316467"/>
<DICH_DATA CI_END="8.899058061258208" CI_START="0.22113274130871421" EFFECT_SIZE="1.4028090048725232" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9493440403025564" LOG_CI_START="-0.6553469502436277" LOG_EFFECT_SIZE="0.1469985450294643" ORDER="32205" O_E="0.38095238095238093" SE="0.9426034311953403" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="1.125490846745202" WEIGHT="4.750207849619704"/>
<DICH_DATA CI_END="16.88339890529524" CI_START="0.06509307633892034" EFFECT_SIZE="1.0483283711713745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2274598816984092" LOG_CI_START="-1.1864652029481138" LOG_EFFECT_SIZE="0.020497339375147663" ORDER="32206" O_E="0.023474178403755874" SE="1.4179515438432495" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="104" TOTAL_2="109" VAR="0.49736729052378464" WEIGHT="2.099171232198417"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.980280437361717" CI_END="1.537190792441819" CI_START="0.5846987185567967" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9480471963557713" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="37" I2="19.683237715043546" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.18672777443680383" LOG_CI_START="-0.23306785797445193" LOG_EFFECT_SIZE="-0.02317004176882408" METHOD="PETO" NO="13" P_CHI2="0.2893269027737301" P_Q="1.0" P_Z="0.8287110205567784" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="528" WEIGHT="100.0" Z="0.21635502554583652">
<NAME>Adverse events - Insomnia</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7554147761509897" CI_START="0.6873981612538855" EFFECT_SIZE="1.3762510856010168" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.44018698301899906" LOG_CI_START="-0.1627916339072008" LOG_EFFECT_SIZE="0.13869767455589918" ORDER="32207" O_E="2.5456919060052208" SE="0.3541926243747417" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="7.971149847636838" WEIGHT="48.469887208005844"/>
<DICH_DATA CI_END="1.7818120066462124" CI_START="0.3518054405689521" EFFECT_SIZE="0.7917393245312623" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.25086188107961116" LOG_CI_START="-0.45369744858860833" LOG_EFFECT_SIZE="-0.10141778375449856" ORDER="32208" O_E="-1.363387978142077" SE="0.41386163787204167" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="5.838343667947399" WEIGHT="35.5010085716655"/>
<DICH_DATA CI_END="1.3774290352852239" CI_START="0.06659620849422684" EFFECT_SIZE="0.3028721697678024" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.13906923338376373" LOG_CI_START="-1.1765504957081987" LOG_EFFECT_SIZE="-0.5187406311622175" ORDER="32209" O_E="-2.0" SE="0.7728015412913087" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="1.6744186046511627" WEIGHT="10.1815776215133"/>
<DICH_DATA CI_END="4.573662115444573" CI_START="0.04389702943706388" EFFECT_SIZE="0.44807385609612865" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6602640774508447" LOG_CI_START="-1.3575648679752264" LOG_EFFECT_SIZE="-0.34865039526219094" ORDER="32210" O_E="-0.5714285714285714" SE="1.1852827109576451" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="0.7117969138875063" WEIGHT="4.32819816345095"/>
<DICH_DATA CI_END="391.1477443820738" CI_START="0.15367250908059635" EFFECT_SIZE="7.752977189467862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5923408301585664" LOG_CI_START="-0.8134038177471691" LOG_EFFECT_SIZE="0.8894685062056986" ORDER="32211" O_E="0.511737089201878" SE="2.0005512648877297" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="104" TOTAL_2="109" VAR="0.24986224073706717" WEIGHT="1.5193284353643997"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8530146802447094" CI_END="2.212743227674898" CI_START="0.824128153605087" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3504014183293331" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.3449310202201287" LOG_CI_START="-0.08400524937574957" LOG_EFFECT_SIZE="0.1304628854221896" METHOD="PETO" NO="14" P_CHI2="0.3959342171016742" P_Q="1.0" P_Z="0.23315791239962114" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="394" TOTAL_2="399" WEIGHT="99.99999999999999" Z="1.1922636292220152">
<NAME>Adverse events - Sleep disorder</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.492546708962294" CI_START="0.9413016024574883" EFFECT_SIZE="2.056414699485812" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6524926011597817" LOG_CI_START="-0.02627120197504252" LOG_EFFECT_SIZE="0.31311069959236965" ORDER="32212" O_E="4.535248041775457" SE="0.3987092178964096" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="192" VAR="6.290533032470056" WEIGHT="39.93449457223829"/>
<DICH_DATA CI_END="2.0366663707637622" CI_START="0.5153256814636032" EFFECT_SIZE="1.0244737602436869" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.30891989242517925" LOG_CI_START="-0.2879182137585829" LOG_EFFECT_SIZE="0.01050083933329813" ORDER="32213" O_E="0.19672131147541094" SE="0.3505856579686154" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="8.136014401784761" WEIGHT="51.650253053380304"/>
<DICH_DATA CI_END="5.486741038992973" CI_START="0.1822575537816048" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7393144630226903" LOG_CI_START="-0.7393144630226903" LOG_EFFECT_SIZE="0.0" ORDER="32214" O_E="0.0" SE="0.8685539504902852" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="22" VAR="1.3255813953488371" WEIGHT="8.41525237438139"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.520652219437228" CI_START="0.06053029787912725" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="1.2180271888506577" LOG_CI_START="-1.2180271888506577" LOG_EFFECT_SIZE="0.0" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.0">
<NAME>Adverse events - Vivid dreams</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.520652219437228" CI_START="0.06053029787912725" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2180271888506577" LOG_CI_START="-1.2180271888506577" LOG_EFFECT_SIZE="0.0" ORDER="32215" O_E="0.0" SE="1.4309504001254019" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="0.4883720930232558" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.399510684758979" CI_END="1.729385323132445" CI_START="0.5478991412232809" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9734108759349326" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="31.810598610596376" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.23789176890487593" LOG_CI_START="-0.26129938027761473" LOG_EFFECT_SIZE="-0.011703805686369402" METHOD="PETO" NO="16" P_CHI2="0.2214309988738633" P_Q="1.0" P_Z="0.9267736578233408" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="498" TOTAL_2="508" WEIGHT="100.0" Z="0.09190482509517905">
<NAME>Adverse events - Somnolence</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.085170721630163" CI_START="0.8221870339347772" EFFECT_SIZE="2.2367718852408376" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7842727670232491" LOG_CI_START="-0.08502937641845154" LOG_EFFECT_SIZE="0.3496216953023987" ORDER="32216" O_E="3.087431693989071" SE="0.5106323821726647" STUDY_ID="STD-Gershanik-1994" TOTAL_1="181" TOTAL_2="185" VAR="3.835158303871605" WEIGHT="32.97556551260555"/>
<DICH_DATA CI_END="1.3338053056636214" CI_START="0.2389833110407586" EFFECT_SIZE="0.5645858732125906" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.12509244063987723" LOG_CI_START="-0.621632426147988" LOG_EFFECT_SIZE="-0.2482699927540553" ORDER="32217" O_E="-2.971279373368146" SE="0.43862988309889656" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="191" TOTAL_2="192" VAR="5.197608545971408" WEIGHT="44.6902233327724"/>
<DICH_DATA CI_END="4.054085771921184" CI_START="0.10210266143436847" EFFECT_SIZE="0.6433762095355711" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.607892932782747" LOG_CI_START="-0.9909629373333076" LOG_EFFECT_SIZE="-0.1915350022752803" ORDER="32218" O_E="-0.5" SE="0.9391758525703704" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="22" VAR="1.1337209302325582" WEIGHT="9.74799104645966"/>
<DICH_DATA CI_END="5.301931496295504" CI_START="0.20765994484697592" EFFECT_SIZE="1.0492849003503142" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7244341121233949" LOG_CI_START="-0.68264726566778" LOG_EFFECT_SIZE="0.020893423227807448" ORDER="32219" O_E="0.07042253521126751" SE="0.8265265664796889" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="104" TOTAL_2="109" VAR="1.4638155801671577" WEIGHT="12.5862201081624"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.168007954424733" CI_END="1.1981287739268398" CI_START="0.6314242529974384" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8697859311758794" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="99" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.07850349818710002" LOG_CI_START="-0.19967874087796453" LOG_EFFECT_SIZE="-0.06058762134543223" METHOD="PETO" NO="17" P_CHI2="0.5301137764756289" P_Q="1.0" P_Z="0.39324149060568336" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="531" TOTAL_2="540" WEIGHT="100.0" Z="0.8537536842402282">
<NAME>All cause withdrawal rate</NAME>
<GROUP_LABEL_1>Cabergoline</GROUP_LABEL_1>
<GROUP_LABEL_2>Bromocriptine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cabergoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBromocriptine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3841959064955787" CI_START="0.46730180472869054" EFFECT_SIZE="0.8042619257452448" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.14119756056070404" LOG_CI_START="-0.33040254171868233" LOG_EFFECT_SIZE="-0.09460249057898915" ORDER="32220" O_E="-2.838541666666668" SE="0.2770202345370675" STUDY_ID="STD-Gershanik-1994" TOTAL_1="191" TOTAL_2="193" VAR="13.030978095196001" WEIGHT="34.794533292989044"/>
<DICH_DATA CI_END="2.1319819801957767" CI_START="0.605700531284524" EFFECT_SIZE="1.1363725701078908" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.32878352965349716" LOG_CI_START="-0.21774204539921127" LOG_EFFECT_SIZE="0.05552074212714295" ORDER="32221" O_E="1.2404371584699447" SE="0.3210318281311887" STUDY_ID="STD-Gershanik-1994b" TOTAL_1="181" TOTAL_2="185" VAR="9.70295050879516" WEIGHT="25.908234366763402"/>
<DICH_DATA CI_END="1.3154104598399905" CI_START="0.12434751790645691" EFFECT_SIZE="0.40443544071865656" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.1190612909463242" LOG_CI_START="-0.905362879234317" LOG_EFFECT_SIZE="-0.3931507941439964" ORDER="32222" O_E="-2.5" SE="0.6017518285455348" STUDY_ID="STD-Inzelberg-1996" TOTAL_1="22" TOTAL_2="22" VAR="2.761627906976744" WEIGHT="7.373932597398374"/>
<DICH_DATA CI_END="2.234925864970333" CI_START="0.10613483595895953" EFFECT_SIZE="0.4870354094509578" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34926312166558826" LOG_CI_START="-0.9741420469976403" LOG_EFFECT_SIZE="-0.31243946266602596" ORDER="32223" O_E="-1.1904761904761907" SE="0.7773747470340178" STUDY_ID="STD-Korczyn-1994" TOTAL_1="22" TOTAL_2="20" VAR="1.6547757314307838" WEIGHT="4.418482546672769"/>
<DICH_DATA CI_END="1.8531230132524434" CI_START="0.5463588586440435" EFFECT_SIZE="1.0062157693296283" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.2679042494341235" LOG_CI_START="-0.26252201089418814" LOG_EFFECT_SIZE="0.0026911192699676767" ORDER="32224" O_E="0.06382978723404165" SE="0.3115750109691849" STUDY_ID="STD-Yanagisawa-1996" TOTAL_1="115" TOTAL_2="120" VAR="10.300890297268747" WEIGHT="27.50481719617642"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>